ClinicalTrials.Veeva

Menu

Polygenic Risk Score to Predict Weight Loss Intervention in Children With Obesity

F

Far Eastern Memorial Hospital

Status

Enrolling

Conditions

Children
Obesity

Study type

Observational

Funder types

Other

Identifiers

NCT05466097
111078-F

Details and patient eligibility

About

Children with obesity are prone to suffering from metabolic diseases, which undoubtedly increases the burden of public health. Since obesity is a multiple gene disease, a comprehensive approach using polygenic risk scores (PRS), rather than individual genetic variant, may be a more appropriate method. The aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes.

Full description

The investigators hypothesize that obesity gene variants can predict the efficacy of weight loss intervention in obese children. The aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes. The investigators will also analyze whether these gene variants have an effect on obesity comorbidities (hypertension, hyperlipidemia, non-alcoholic fatty liver disease, type 2 diabetes, obstructive sleep apnea, polycystic ovary syndrome, etc.). For participants with non-simple obesity, the investigators will collect their complete family history, and perform whole exome sequencing to identify possible rare disease-causing genes.

The experimental design is as follows:

Obese children and adolescent subjects will undergo a 6-month weight loss intervention program and be followed for 12-18 months. The investigators will analyze obesity and fatty liver-related genes in these adolescents using next-generation gene sequencing and/or gene chips, perform polygenic risk score analysis, and use an additive model to total the number of variant loci weighted by effect size. Whole exome gene sequencing refers to the human DNA map (hg19), and Sanger sequencing will be used to confirm the correctness of the variant site.

Enrollment

300 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age <18 years old
  • Obesity definition: BMI > 95% according to the age- and gender-specific standard by National Health Institute in Taiwan
  • Willing to give written informed consent

Exclusion criteria

  • Alcohol consumption
  • Major systemic diseases, including cardiopulmonary disease, renal failure, cancer, and major psychotic disorder

Trial contacts and locations

1

Loading...

Central trial contact

Yu-Cheng Lin,, M.D., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems